ImmunityBio Inc is a biotechnology company focused on developing innovative immunotherapy treatments to harness the body's immune system in the fight against cancer and infectious diseases
The company specializes in the discovery and commercialization of novel therapies that aim to stimulate an immune response, with a particular emphasis on enhancing the effectiveness of existing cancer treatments. By leveraging cutting-edge research and technology, ImmunityBio is dedicated to improving patient outcomes and finding breakthrough solutions for complex medical challenges.
Stocks fell broadly on Monday to start the month of March with all three major indices red in midday trading. Investors digested a decline in February's ISM Manufacturing PMI data which fell to 50.3%, down from 50.9% in January.
The study will evaluate a combination therapy using BeiGene’s tislelizumab and ImmunityBio’s Anktiva for certain patients with advanced or metastatic non-small cell lung cancer
Explore this week's top-performing mid-cap stocks, including H&E Equipment Services' impressive 100.59% surge following an acquisition announcement by United Rentals. Discover why stocks like SEMrush and Blueprint Medicines also experienced significant gains, impacting investment portfolios positively.
The Washington Post is not endorsing a candidate in a presidential election for the first time since 1988. Sources say the decision came from Jeff Bezos.
EF Hutton rates ImmunityBio (IBRX) as a Buy with a $30 target. Anktiva shows promise in cancer treatment, boosting response rates and survival outcomes.
